The Pfizer story
What drives Pfizer, what its price assumes and what could change the story, written from its own filings.
- Growth remains uneven. In the quarter to June 2026, launched and acquired products grew 18% operationally, but Pfizer’s total revenue grew only 1% operationally.
- Research carries real costs. Pfizer invested $5.3 billion in internal research during the first six months of 2026, while drug asset impairments drove a reported loss in the quarter to June 2026.
- Cash must stretch. At the end of June 2026, Pfizer had $63.2 billion of debt against $8.3 billion of cash, alongside commitments to research, dividends and restructuring.
